Business Wire

SAMSUNG-ELECTRONICS

12.2.2020 11:05:04 CET | Business Wire | Press release

Share
Samsung’s 108Mp ISOCELL Bright HM1 Delivers Brighter Ultra-High-Res Images with Industry-First Nonacell Technology

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced its next-generation 108-megapixel (Mp) image sensor, Samsung ISOCELL Bright HM1. With a spectrum of light-enhancing technologies spanning from Nonacell and Smart-ISO to real-time HDR, ISOCELL Bright HM1 allows brighter and more detailed 108Mp photographs and crystal-clear 8K videos at 24 frames per second (fps), even under extreme lighting conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005343/en/

“To capture meaningful moments in our lives, Samsung has been driving innovations in pixel and logic technologies that enable ISOCELL image sensors to take astounding photographs even when lighting conditions aren’t ideal,” said Yongin Park, executive vice president of the sensor business at Samsung Electronics. “By adopting Nonacell and Smart-ISO technologies, the 108Mp ISOCELL Bright HM1 helps take vivid high-resolution pictures across a wide range of lighting environments.”

At a 1/1.33” scale with 108-million 0.8μm pixels, the ISOCELL Bright HM1 features the industry's first state-of-the-art Nonacell technology, which delivers brighter images in low-light settings. In 2017, Samsung introduced Tetracell, a pixel-binning technology with a special two-by-two array that merges four neighboring pixels to work as a single large pixel. Nonacell is an enhanced version of Tetracell with a three-by-three pixel structure. In the HM1, Nonacell merges nine neighboring 0.8μm pixels to mimic a large 2.4μm pixel, more than doubling Tetracell’s light absorption.

As the number of adjoined cells increase, so does color interference, making pixel-binning technologies more challenging, While such difficulties had limited Nonacell to a theory, the HM1 was able to realize the method by adopting Samsung’s ISOCELL Plus technology, which dramatically reduces crosstalk and minimizes optical loss as well as light reflection.

For ultimate results under any lighting condition, the HM1 supplements Nonacell with several other advanced pixel technologies. For example, the HM1’s Smart-ISO technology produces vivid and vibrant images by intelligently selecting the optimal ISO. High ISOs are used in darker settings while low ISOs are better for brighter environments to control light saturation.

In challenging mixed-light environments for photo-taking, the HM1’s real-time HDR technology optimizes exposures, producing more natural looking videos and still photographs. By assigning the most appropriate exposure lengths to each pixel, the HM1 is able to capture scenes in multiple exposures simultaneously, generating HDR images in real-time for both preview and capture modes. For sharper results, the HM1 supports a gyro-based electronic image stabilization (EIS) and Super-PD, an advanced phase detection technology for fast and accurate auto-focus.

The HM1 allows users to preview and capture full shots and close-ups of the subject at up to 3x lossless zoom, preserving the quality of the image. This is made possible by the sensor directly converting the pixels using an embedded hardware IP, rather than having the task delegated to the mobile processor. With 108-million pixels, the sensor is also able to produce images up to 3x zoom at a 12Mp resolution without upscaling.

Samsung ISOCELL Bright HM1 is currently in mass production.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

# # #

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0um-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. In June 2018, Samsung introduced an upgraded pixel isolation technology, the ISOCELL Plus.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye